DOCKCOV2

The current state of the COVID-19 pandemic is a global health crisis. To fight the novel coronavirus, one of the best-known ways is to block enzymes essential for virus replication. Currently, we know that the SARS-CoV-2 virus encodes about 29 proteins such as spike protein, 3C-like protease (3CLpro), RNA-dependent RNA polymerase (RdRp), Papain-like protease (PLpro), and nucleocapsid (N) protein. SARS-CoV-2 uses human angiotensin-converting enzyme 2 (ACE2) for viral entry and transmembrane serine protease family member II (TMPRSS2) for the spike protein priming. Thus in order to speed up the discovery of therapeutic agents, we develop DockCoV2, a drug database for SARS-CoV2. DockCoV2 focuses on predicting the binding affinity of FDA-approved and Taiwan National Health Insurance (NHI) drugs with the seven proteins mentioned above, 5 major SARS-CoV-2 variant proteins and other 67 human proteins, that were identified to be associated with SARS-CoV-2 from GWAS analysis and protein-virus..

Also known as: Taiwan AI, Taiwan AI Labs